



Commercial/Healthcare Exchange PA Criteria Effective: October 3, 2023

Prior Authorization: Litfulo (ritlecitinib)

Products Affected: Litfulo (ritlecitinib) oral capsules

Medication Description: LITFULO is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.

Covered Uses:

1. Severe alopecia areata

Exclusion Criteria:

1. Concurrent Use with an Oral or Topical Janus Kinase Inhibitor (JAKi)
Note: Examples include Olumiant (baricitinib tablets), Rinvoq (upadacitinib tablets), Xeljanz (tofacitinib tablets), and Opzelura (ruxolitinib cream).
2. Concurrent Use with a Biologic Immunomodulator
Note: Examples include Adbry (tralokinumab-ldrm subcutaneous injection), Cinqair (reslizumab intravenous), Dupixent (dupilumab subcutaneous injection), Fasentra (benralizumab subcutaneous injection), Nucala (mepolizumab subcutaneous injection), Tezspire (tezepelumab-ekko subcutaneous injection), and Xolair (omalizumab subcutaneous injection).
3. Concurrent Use with Other Potent Immunosuppressants (e.g., cyclosporine, azathioprine).

Required Medical Information:

1. Diagnosis
2. Previous Therapies tried and failed

Prescriber Restriction: The medication must be prescribed by, or in consultation with, a dermatologist.

Age Restriction: 12 years of age or older

Coverage Duration: 12 months

Other Criteria:

Initial Approval Criteria

1. Alopecia Areata.

Note: Alopecia universalis and alopecia totalis are subtypes of alopecia areata.

- A. Patient has a current episode of alopecia areata lasting for ≥ 6 months; **AND**
- B. Patient has $\geq 50\%$ scalp hair loss; **AND**
- C. Patient has tried at least one of the following for alopecia areata (i or ii):
 - i. Conventional systemic therapy; **OR**

August 2023



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

Page 1 of 2

Note: Examples of conventional systemic therapies include corticosteroids, methotrexate, and cyclosporine. An exception to the requirement for a trial of one conventional systemic agent can be made if the patient has already tried Olumiant (baricitinib tablet).

- ii. Topical corticosteroid; **AND**
- D. Patient does not have hair loss due to androgenetic alopecia, chemotherapy-induced hair loss, or other causes of hair loss other than alopecia areata

Renewal Criteria

1. Alopecia Areata.

- A. Patient has been established on Litfulo for at least 6 months; **AND**
Note: A patient who has received < 6 months of therapy or who is restarting therapy with the requested drug is reviewed under criterion A (Initial Therapy).
- B. Patient experienced a beneficial clinical response, defined as improvement from baseline (prior to initiating Litfulo) in extent and density of scalp hair loss; **AND**
- C. According to the prescriber, the patient continues to require systemic therapy for treatment of alopecia areata.

Note: International consensus states that systemic treatment is best discontinued once complete regrowth has been achieved and maintained for 6 months or when regrowth is sufficient to be managed topically.

References:

- 1. Litfulo (ritlecitinib) [prescribing information]. New York, NY: Pfizer; June 2023.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	10/3/2023